相似文献
1
Alzheimer disease.
Dis Mon. 2010 Sep;56(9):484-546. doi: 10.1016/j.disamonth.2010.06.001.
2
Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.
Brain. 2011 Jan;134(Pt 1):301-17. doi: 10.1093/brain/awq349. Epub 2010 Dec 13.
3
Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
Brain. 2020 Jan 1;143(1):320-335. doi: 10.1093/brain/awz378.
4
Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.
Arch Neurol. 2008 Oct;65(10):1304-9. doi: 10.1001/archneur.65.10.noc80013. Epub 2008 Aug 11.
5
Quantification of Tau Load in Alzheimer's Disease Clinical Trials Using Positron Emission Tomography.
Methods Mol Biol. 2018;1750:221-229. doi: 10.1007/978-1-4939-7704-8_15.
6
Does a positive Pittsburgh Compound B scan in a patient with dementia equal Alzheimer disease?
JAMA Neurol. 2013 Jul;70(7):912-4. doi: 10.1001/jamaneurol.2013.420.
7
Alzheimer's disease.
Lancet. 2011 Mar 19;377(9770):1019-31. doi: 10.1016/S0140-6736(10)61349-9. Epub 2011 Mar 1.
8
Senile dementia associated with amyloid beta protein angiopathy and tau perivascular pathology but not neuritic plaques in patients homozygous for the APOE-epsilon4 allele.
Acta Neuropathol. 2000 Jul;100(1):1-12. doi: 10.1007/s004010051186.
9
Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.
Brain. 2024 Jun 3;147(6):2144-2157. doi: 10.1093/brain/awae116.
10
Beyond diagnosis: what biomarkers are teaching us about the "bio"logy of Alzheimer disease.
Ann Neurol. 2010 Mar;67(3):283-5. doi: 10.1002/ana.22020.
引用本文的文献
1
Alzheimer's disease risk prediction using machine learning for survival analysis with a comorbidity-based approach.
Sci Rep. 2025 Aug 6;15(1):28723. doi: 10.1038/s41598-025-14406-0.
2
Dual Inhibitors of Acetylcholinesterase and Monoamine Oxidase-B for the Treatment of Alzheimer's Disease.
Molecules. 2025 Jul 15;30(14):2975. doi: 10.3390/molecules30142975.
3
Unveiling the Polypharmacological Potency of FDA-Approved Rebamipide for Alzheimer's Disease.
Pharmaceuticals (Basel). 2025 May 22;18(6):772. doi: 10.3390/ph18060772.
4
Constipation and risk of cognitive impairment and dementia in adults: a systematic review and meta-analysis.
Front Neurol. 2025 Jun 4;16:1600952. doi: 10.3389/fneur.2025.1600952. eCollection 2025.
5
2D-QSAR and molecular docking based virtual screening and molecular dynamic simulation of the indole based herbal molecules for the discovery of potent molecules in the treatment of Alzheimer's disease.
In Silico Pharmacol. 2025 Jun 7;13(2):81. doi: 10.1007/s40203-025-00364-y. eCollection 2025.
6
Drawing the mind: assessing cognitive decline through self-figure drawings.
Front Psychol. 2025 May 7;16:1558675. doi: 10.3389/fpsyg.2025.1558675. eCollection 2025.
7
Advancing Remote Monitoring for Patients With Alzheimer Disease and Related Dementias: Systematic Review.
JMIR Aging. 2025 May 14;8:e69175. doi: 10.2196/69175.
8
DNA methylation in peripheral blood leukocytes in late onset Alzheimer's disease.
J Alzheimers Dis Rep. 2025 May 7;9:25424823251341176. doi: 10.1177/25424823251341176. eCollection 2025 Jan-Dec.
9
Biomarkers in Alzheimer's disease: new frontiers with olfactory models.
Inflammopharmacology. 2025 May 1. doi: 10.1007/s10787-025-01705-1.
10
Amyloid-β-Induced Neurotoxicity Modulates miR-98 and miR-200 Expression in SH-SY5Y Cells: A Step Toward Alzheimer's Biomarker Discovery.
Mol Neurobiol. 2025 Apr 7. doi: 10.1007/s12035-025-04895-5.
本文引用的文献
1
Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report.
Arch Neurol. 2009 Dec;66(12):1557-62. doi: 10.1001/archneurol.2009.279.
2
High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types.
Arch Neurol. 2009 Dec;66(12):1537-44. doi: 10.1001/archneurol.2009.285.
3
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease.
Arch Neurol. 2009 Dec;66(12):1469-75. doi: 10.1001/archneurol.2009.269.
4
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.
Nat Genet. 2009 Oct;41(10):1088-93. doi: 10.1038/ng.440. Epub 2009 Sep 6.
5
Neuropathological correlates of dementia in over-80-year-old brain donors from the population-based Cambridge city over-75s cohort (CC75C) study.
J Alzheimers Dis. 2009;18(3):645-58. doi: 10.3233/JAD-2009-1182.
6
Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury.
J Neuropathol Exp Neurol. 2009 Jul;68(7):709-35. doi: 10.1097/NEN.0b013e3181a9d503.
7
Comparison of Abeta levels in the brain of familial and sporadic Alzheimer's disease.
Neurochem Int. 2009 Sep;55(4):243-52. doi: 10.1016/j.neuint.2009.03.007. Epub 2009 Mar 20.
8
RNA granules: post-transcriptional and epigenetic modulators of gene expression.
Nat Rev Mol Cell Biol. 2009 Jun;10(6):430-6. doi: 10.1038/nrm2694.
9
In vivo mapping of amyloid toxicity in Alzheimer disease.
Neurology. 2009 Apr 28;72(17):1504-11. doi: 10.1212/WNL.0b013e3181a2e896.
10
Synaptic degeneration in Alzheimer's disease.
Acta Neuropathol. 2009 Jul;118(1):167-79. doi: 10.1007/s00401-009-0536-x. Epub 2009 Apr 24.
Zotero 插件